Biotech Outlook 2026: Advancing AI, Organoids, and Translational Science

The Asia-Pacific biotech sector is entering 2026 with renewed momentum. Investment in the pre-clinical organoid space continues to grow as the industry increasingly explores human-relevant models and aims to reduce reliance on animal testing where scientifically feasible. At the same time, pharmaceutical companies are expanding their focus on next-generation drug modalities – particularly antibody-drug conjugates (ADCs) and targeted protein degradation (TPD) – further strengthening demand for advanced discovery platforms and more predictive research tools.

- Kyon SoonPil

Growth Opportunities: AI, Multi-omics, and Organoid Models

Three converging forces are driving R&D acceleration across APAC: AI-powered discovery, multi-omics integration, and organoid-based physiological models. Together, these technologies are reshaping how scientists interrogate complex biology – with AI providing computational power, multi-omics offering molecular depth, and organoids and microphysiological systems delivering human-relevant context. This convergence enables richer biological insights, more predictive translational models, and faster design-to-data cycles. Supported by rising global and regional investment, these approaches are becoming foundational to next-generation drug discovery.

Investment Focus: Automation, Digital Labs, and New Alternative Methods